poster

Genotoxic Potential of an Antiviral Pyrimidine Nucleoside Analogue, 5-(2-chloroethyl)-2′-deoxyuridine (CEDU)

5-(2-Chloroethyl)-2'-deoxyuridine (CEDU) is a nucleoside analogue developed as an antiviral drug by Novartis.  In studies conducted by Novartis, CEDU was evaluated negative in an in vitro and in vivo micronucleus assay, but positive in Ames assay, Pig-a assay, and Transgenic Rodent Assay using MutaMouse®. 

Given the unusual and interesting genotoxic profile CEDU, an in vivo study was conducted with CEDU to further investigate its genotoxic potential. In this study, male and female Sprague‑Dawley rats were administered CEDU at dose levels of 30, 100, 300, and 1000 mg/kg/day for 28 consecutive days. Blood was collected on Days -5 and 29 to conduct the  Pig-a assay and Days 4 and 29 to conduct peripheral blood micronucleus assay.